NBI-1117570

DRUG2 trials

Sponsors

Neurocrine Biosciences Inc., Neurocrine Biosciences

Conditions

Schizophrenia

Phase 2

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

RecruitingNCT07288333

Neurocrine BiosciencesSchizophrenia

Start: 2026-02-16End: 2027-08-01Target: 120Updated: 2026-07-22

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults with Schizophrenia Who Warrant Inpatient Hospitalization

Not yet recruitingCTIS2025-521868-35-00

Neurocrine Biosciences Inc.Schizophrenia

Target: 73Updated: 2026-03-23